Study Evaluating Etanercept for the Treatment of Refractory Heel Enthesitis in Spondylarthropathy

• Status: Completed
• Trial end date: 2008-09-01
• Target enrollment: 0
• Participant gender: All

Summary

To assess the efficacy and safety of Etanercept in patients with spondylarthropathy and refractory heel enthesitis.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
• Treatments: Etanercept

Criteria

Inclusion criteria

• Spondylarthropathy

• Heel enthesitis refractory to standard treatment

• Between 18 and 70 years of age

• The patient global assessment of the disease activity (measured by a 100 mm VAS) must be >40 in the last 48 hours

Exclusion criteria

• Use of > 1 local steroid injection within 2 weeks of screening

• Prior exposure to any TNF-inhibitor, including etanercept

• Dose of NSAIDs changed within two weeks of study drug evaluation